Drug · CHEMBL193

NIFEDIPINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. NIFEDIPINE. Drugs and targets, record CHEMBL193. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL193

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: NIFEDIPINE; ChEMBL
ChEMBL ID: CHEMBL193; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Adalat, Adalat a.r., Adalat cc, Adalat ic, Adalat la 20, Adalat la 30, Adalat la 60, Adalat ret, Adalate lp, Adanif xl, Adipine mr 10, Adipine mr 20, Adipine xl, Afeditab cr, Angiopine 10, Angiopine 40 la, Angiopine 5, Angiopine mr 10, Angiopine mr 20, Calanif, Calchan mr 10, Calchan mr 20, Calcilat, Cardilate mr, Coracten sr, Coracten xl, Coroday mr, Fortipine la40, Genalat 10 ret, Genalat 20 ret, Hypolar ret 10, Hypolar ret 20, Hypolar xl 30, Kentipine, Kentipine mr 10, Kentipine mr 20, Neozipine xl, Nife-wolff, Nifedipress mr 10, Nifedipress mr 20, Nifedotard 20 mr, Nifelease, Nifensar xl, Nifopress mr, Nifopress ret, Nimodrel mr 10, Nimodrel mr 20, Nimodrel xl, Nivaten ret, Procardia, Procardia xl, Slofedipine xl 30, Slofedipine xl 60, Tensipine mr 10, Tensipine mr 20, Unipine xl, Valni 20 ret, Valni xl, Vasad; ChEMBL
Other names: BAY A 1040, BAY-A-1040, Coracten, NSC-757242, Nifedipine hydrochloride, Nifedipine slow release, Nifedipino, Nifedipinum; ChEMBL
DrugBank: DB01115; DrugBank
InChIKey: HYIMSNHJOBLJNT-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 4 of its 26 diseases, from ATC, DailyMed and TTD; Open Targets

Targets4

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
CACNA1C	Voltage-gated L-type calcium channel	Voltage-gated L-type calcium channel blocker	BLOCKER	https://conductscience.org/library/genes/775
CACNA1D	Voltage-gated L-type calcium channel	Voltage-gated L-type calcium channel blocker	BLOCKER	https://conductscience.org/library/genes/776
CACNA1F	Voltage-gated L-type calcium channel	Voltage-gated L-type calcium channel blocker	BLOCKER	https://conductscience.org/library/genes/778
CACNA1S	Voltage-gated L-type calcium channel	Voltage-gated L-type calcium channel blocker	BLOCKER	https://conductscience.org/library/genes/779

Source ChEMBL

Diseases26

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hypertensive disorder	Approval	DailyMed	74	32	https://conductscience.org/library/drugs?q=MONDO_0005044
premature birth	Phase 3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=EFO_0003917
essential hypertension	Phase 3	ClinicalTrials.gov	8	8	https://conductscience.org/library/drugs?q=MONDO_0001134
preeclampsia	Phase 3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0005081
Anal fissure	Phase 2/3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=HP_0012390
chronic kidney disease	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005300
high altitude pulmonary edema	Unknown	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=EFO_1002002
Infertility	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0000789
Proteinuria	Phase 1	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0000093
congenital adrenal hyperplasia	Phase 1/2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0018479

1 to 10 of 26Source Open Targets

See all 26 diseases

Trials149

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT02299414	Chronic Hypertension and Pregnancy (CHAP) Project	Phase 4	2,408	2023-05-17	nifedipine	Its name	ClinicalTrials.gov
NCT01167153	Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients	Phase 4	564	2012-06-01	nifedipine	Its name	ClinicalTrials.gov
NCT01788358	Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension	Phase 3	508	2015-08-17	nifedipine	Its name	ClinicalTrials.gov
NCT00811057	Tocolysis for Preterm Labor		301	2013-04-04	nifedipine	Its name	ClinicalTrials.gov
NCT00185900	Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial		192	2018-10-02	nifedipine	Its name	ClinicalTrials.gov
NCT04790279	Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension	Phase 4	175	2024-10-28	nifedipine	Its name	ClinicalTrials.gov
NCT02463357	Three New Ideas to Protect Special Forces From the Stress of High Altitude	Phase 4	148	2021-03-30	nifedipine	Its name	ClinicalTrials.gov
NCT04392375	Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor	Phase 4	110	2023-07-24	nifedipine	Its name	ClinicalTrials.gov
NCT03506724	Response to Anti-hypertensives in Pregnant and Postpartum Patients	Phase 4	109	2021-05-24	nifedipine	Its name	ClinicalTrials.gov
NCT00661895	Black Education and Treatment of Hypertension (BEAT HTN)	Phase 4	99	2012-12-04	nifedipine	Its name	ClinicalTrials.gov

1 to 10 of 149

See all 149 trials

Comparisons in its trials111

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Superimposed Preeclampsia	295 of 1,208	373 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Neonatal Hospital Stay of 3 or More Days	590 of 1,208	592 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Hypoglycemia	191 of 1,208	195 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Low Birth Weight	232 of 1,208	277 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Bronchopulmonary Dysplasia (BPD)	8 of 1,208	14 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: 5-min Apgar Score	68 of 1,208	80 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Superimposed Gestational Hypertension	132 of 1,208	156 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Bradycardia	31 of 1,208	35 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Necrotizing Enterocolitis (NEC)	2 of 1,208	2 of 1,200	2,408	NCT02299414	Trial comparisons
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Cesarean Delivery	592 of 1,208	582 of 1,200	2,408	NCT02299414	Trial comparisons

1 to 10 of 111

See all 111 comparisons in its trials

Papers from its trials76

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39878173	RESULT	1	PubMed
39228195	RESULT	1	PubMed
37546514	RESULT	1	PubMed
34530908	RESULT	1	PubMed
30451751	RESULT	1	PubMed
28598453	RESULT	1	PubMed
26829251	RESULT	1	PubMed
23849325	RESULT	1	PubMed
23266540	RESULT	1	PubMed
22801444	RESULT	1	PubMed

1 to 10 of 76

See all 76 papers from its trials

Tests in its trials5

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	Source
Dimensional Change Card Sort	1	ConductCognition
Pattern and Letter Comparison	1	ConductCognition
Picture Order Memory Test	1	ConductCognition
Size Order Memory Test	1	ConductCognition
Vocabulary Test	1	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL193

GET https://conductscience.org/api/drugs/v1/CHEMBL193/diseases?page=2

API reference For AI assistants